Want to see AU:XRF full AI Analyst Report?
Top Page
XRF Scientific Limited
(Sydney:XRF)
Select Model
Select Model
Rating:72Outperform
Price Target:
AU$2.00
â–²(8.70% Upside)
Action:Reiterated
Date:10/14/26
The score is primarily supported by strong financial performance (healthy margins, consistent profitability, and very low leverage). Offsetting this are weak technical momentum signals (negative MACD with subdued RSI/Stochastic) and a somewhat elevated P/E despite a moderate dividend yield.
Positive Factors
Strong profitability
XRF’s strong gross, operating, and net margins indicate that its equipment, consumables, and service offerings generate meaningful economic value. Sustained profitability provides internal funding for product development, customer support, and expansion while helping the company withstand moderate revenue fluctuations.
Negative Factors
Moderating revenue growth
Revenue remains above prior years, but the recent slowdown suggests that expansion is becoming less rapid. If this moderation persists, operating leverage and earnings growth may be harder to sustain, placing greater importance on customer retention, new applications, and effective execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong profitability
XRF’s strong gross, operating, and net margins indicate that its equipment, consumables, and service offerings generate meaningful economic value. Sustained profitability provides internal funding for product development, customer support, and expansion while helping the company withstand moderate revenue fluctuations.
Read all positive factors
XRF Scientific Limited (XRF) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$276.98M
Dividend Yield2.35%
Average Volume (3M)219.36K
Price to Earnings (P/E)28.2
Beta (1Y)1.07
Revenue Growth8.35%
EPS Growth-0.81%
CountryAU
Employees48
SectorIndustrials
Sector Strength72
IndustryIndustrial - Machinery
Share Statistics
EPS (TTM)0.07
Shares Outstanding144,635,300
10 Day Avg. Volume446,741
30 Day Avg. Volume219,358
Financial Highlights & Ratios
PEG Ratio-12.60
Price to Book (P/B)3.77
Price to Sales (P/S)3.90
P/FCF Ratio25.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.09
Revenue Forecast (FY)AU$72.15M
XRF Scientific Limited Business Overview & Revenue Model
Company Description
XRF Scientific Limited is a supplier to the scientific, analytical, construction materials, and mining sectors across Australia, Canada, and Europe. The company produces and sells precious metal items, specialized chemical compounds, and various i...
How the Company Makes Money
XRF makes money mainly by selling products and services used in laboratory sample preparation and analytical testing workflows. Key revenue streams include: (1) product sales of laboratory equipment and systems (e.g., sample preparation machinery ...
XRF Scientific Limited Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
78
Positive
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 64.13M | 59.45M | 59.84M | 55.17M | 40.01M |
| Gross Profit | 30.10M | 28.79M | 26.27M | 22.00M | 16.46M |
| EBITDA | 18.72M | 16.51M | 15.32M | 13.22M | 9.44M |
| Net Income | 10.49M | 10.38M | 8.89M | 7.69M | 6.08M |
Balance Sheet | |||||
| Total Assets | 78.65M | 72.79M | 68.23M | 65.55M | 55.56M |
| Cash, Cash Equivalents and Short-Term Investments | 9.46M | 12.23M | 12.05M | 10.40M | 6.65M |
| Total Debt | 2.34M | 4.41M | 3.38M | 4.31M | 3.51M |
| Total Liabilities | 12.26M | 12.62M | 12.69M | 15.97M | 12.21M |
| Stockholders Equity | 66.40M | 60.17M | 54.89M | 49.25M | 43.48M |
Cash Flow | |||||
| Free Cash Flow | 9.69M | 8.39M | 6.45M | 7.63M | 2.63M |
| Operating Cash Flow | 11.39M | 10.14M | 8.09M | 8.42M | 3.15M |
| Investing Cash Flow | -8.17M | -2.21M | -1.64M | -782.43K | -1.11M |
| Financing Cash Flow | -5.99M | -7.75M | -4.80M | -3.88M | -648.95K |
XRF Scientific Limited Technical Analysis
Positive
1.84
Price Trends
1.81
Positive
1.77
Positive
1.79
Positive
Market Momentum
0.03
Negative
58.99
Neutral
58.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:XRF, the sentiment is Positive. The current price of 1.84 is above the 20-day moving average (MA) of 1.82, above the 50-day MA of 1.81, and above the 200-day MA of 1.79, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 58.99 is Neutral, neither overbought nor oversold. The STOCH value of 58.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:XRF.
XRF Scientific Limited Peers Comparison
UnderperformOutperform
Sector (63)
AU:XRF
XRF Scientific Limited
1.92
-0.12
-6.04%
AU:IMD
Imdex Ltd
3.20
-0.23
-6.62%
XRF Scientific Limited Corporate Events
XRF Scientific Delivers Strong September Quarter as Orbis and CGA Integration Drive Growth
Oct 12, 2026
XRF Scientific reported a strong September 2026 quarter, with revenue rising 38% to $21.1 million and profit before tax up 30% to $4.4 million, traditionally its weakest trading period. Growth was broad-based across divisions, supported by robust ...
XRF Scientific Director Increases Indirect Holding via Dividend Reinvestment
Sep 28, 2026
XRF Scientific Limited has disclosed a change in the indirect shareholdings of director David William Kiggins, relating to interests held via Circle K Pty Ltd and Glengarry Estate Pty Ltd . The update records the acquisition of 2,385 ordinary sha...
XRF Scientific Director Lifts Indirect Shareholding via Dividend Reinvestment
Sep 28, 2026
XRF Scientific Limited has reported a change in director Frederick Sheppard Grimwade’s indirect interest in the company’s ordinary shares, held via his personal superannuation fund through Mutual Trust Pty Ltd. His holding increased by...
XRF Scientific Seeks ASX Quotation for 932,007 New Shares
Sep 25, 2026
XRF Scientific Limited, listed on the ASX under ticker XRF, is an Australian company whose ordinary fully paid shares are traded on the local securities market. Its capital structure is composed of these quoted shares, which provide investors with...
XRF Scientific Confirms DRP Pricing for 2026 Dividend
Sep 25, 2026
XRF Scientific Limited has confirmed details of its dividend distribution on ordinary fully paid shares for the 12‑month period ended June 30, 2026, updating an earlier announcement lodged in August. The record date for shareholders is Septe...
XRF Scientific Sets 2026 AGM to Vote on Pay Report and Director Re-election
Sep 14, 2026
XRF Scientific Limited has called its Annual General Meeting for 19 October 2026 at the Quest Hotel in Innaloo, Western Australia, where shareholders will review the company’s financial statements and key reports for the year ended 30 June 2...
XRF Scientific Director Increases Indirect Shareholding Via On-Market Trade
Aug 25, 2026
XRF Scientific Limited has reported a change in the shareholding of director Vance Stazzonelli, in line with ASX disclosure requirements for listed companies. The notice details his direct and indirect holdings in ordinary shares and performance r...
XRF Scientific Director Increases Shareholding in Routine On-Market Trade
Aug 24, 2026
XRF Scientific Limited has reported a change in director Vance Stazzonelli’s holdings following an on-market trade conducted on 24 August 2026. Stazzonelli increased his direct ordinary shareholding by 5,366 shares at a value of $9,865, taki...
XRF Scientific Director Converts Performance Rights Into Ordinary Shares
Aug 21, 2026
XRF Scientific Limited has announced a change in the interests of director Vance Stazzonelli, reflecting the conversion of previously issued performance rights into ordinary shares. Stazzonelli converted 214,634 performance rights, originally gran...
XRF Scientific Seeks ASX Quotation for 663,221 New Ordinary Shares
Aug 21, 2026
XRF Scientific Limited, an ASX-listed company trading under the code XRF, operates within the industrial and scientific sector and raises capital through ordinary fully paid shares. The company’s securities are governed by ASX listing rules,...
XRF Scientific Files Updated Corporate Governance Statement and Appendix 4G
Aug 17, 2026
XRF Scientific Limited has lodged its annual corporate governance disclosures with the ASX, confirming that its corporate governance statement for the year ended 30 June 2026 is available on its website and is current as of 17 August 2026. The fil...
XRF Scientific Declares Full-Year Dividend of 4.5 Cents per Share
Aug 17, 2026
XRF Scientific Limited has declared an ordinary dividend of AUD 0.045 per share, relating to the 12-month period ending 30 June 2026, for its fully paid ordinary shares. The stock will trade ex-dividend on 10 September 2026, with a record date of ...
XRF Scientific posts record year as global growth and new products drive earnings
Aug 17, 2026
XRF Scientific has reported a record full-year result to June 2026, with revenue rising 8% to $64.4 million and adjusted profit before tax up 10% to $16.1 million, driven by strong demand from mining and industrial customers and growing internatio...
XRF Scientific Releases 2026 Annual Financial Report
Aug 17, 2026
XRF Scientific Limited has released its annual financial report for the year ended 30 June 2026, outlining its audited results and key corporate disclosures. The document includes the chairman’s letter, directors’ report, consolidated ...
XRF Scientific Posts Steady Profit and Maintains Dividend for FY2026
Aug 17, 2026
XRF Scientific Limited reported an 8% rise in revenue to $64.4 million for the year ended 30 June 2026, with net profit attributable to members edging up 1% to $10.49 million. The modest earnings growth, combined with slightly lower net tangible a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.